http://streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Fri, 12 Jun 2026 17:01:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++4++++++++++PLIANT+THERAPEUTICS%2C++++++For%3A+Jun+11++Filed+by%3A+Cline+Darren+S/26641876.html si-local-file:///var/storage/secattach/20260612/26641876.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++PLIANT+THERAPEUTICS%2C++++++For%3A+Jun+11++Filed+by%3A+Cline+Darren+S/26641876.html Fri, 12 Jun 2026 17:01:00 -0400 O.38968346 PLRX http://www.streetinsider.com/SEC+Filings/Form++4++++++++++PLIANT+THERAPEUTICS%2C++++++For%3A+Jun+11++Filed+by%3A+Cline+Darren+S/26641876.html si-local-file:///var/storage/secattach/20260612/26641876.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++PLIANT+THERAPEUTICS%2C++++++For%3A+Jun+11++Filed+by%3A+Cline+Darren+S/26641876.html Fri, 12 Jun 2026 17:01:00 -0400 O.38968346 PLRX http://www.streetinsider.com/SEC+Filings/Form++4++++++++++PLIANT+THERAPEUTICS%2C++++++For%3A+Jun+11++Filed+by%3A+Curnutte+John+T/26641878.html si-local-file:///var/storage/secattach/20260612/26641878.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++PLIANT+THERAPEUTICS%2C++++++For%3A+Jun+11++Filed+by%3A+Curnutte+John+T/26641878.html Fri, 12 Jun 2026 17:01:00 -0400 O.38968346 PLRX http://www.streetinsider.com/SEC+Filings/Form++4++++++++++PLIANT+THERAPEUTICS%2C++++++For%3A+Jun+11++Filed+by%3A+Curnutte+John+T/26641878.html si-local-file:///var/storage/secattach/20260612/26641878.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++PLIANT+THERAPEUTICS%2C++++++For%3A+Jun+11++Filed+by%3A+Curnutte+John+T/26641878.html Fri, 12 Jun 2026 17:01:00 -0400 O.38968346 PLRX http://www.streetinsider.com/SEC+Filings/Form++4++++++++++PLIANT+THERAPEUTICS%2C++++++For%3A+Jun+11++Filed+by%3A+Krognes+Steve+E./26641884.html si-local-file:///var/storage/secattach/20260612/26641884.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++PLIANT+THERAPEUTICS%2C++++++For%3A+Jun+11++Filed+by%3A+Krognes+Steve+E./26641884.html Fri, 12 Jun 2026 17:01:00 -0400 O.38968346 PLRX http://www.streetinsider.com/SEC+Filings/Form++4++++++++++PLIANT+THERAPEUTICS%2C++++++For%3A+Jun+11++Filed+by%3A+Krognes+Steve+E./26641884.html si-local-file:///var/storage/secattach/20260612/26641884.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++PLIANT+THERAPEUTICS%2C++++++For%3A+Jun+11++Filed+by%3A+Krognes+Steve+E./26641884.html Fri, 12 Jun 2026 17:01:00 -0400 O.38968346 PLRX http://www.streetinsider.com/SEC+Filings/Form++4++++++++++PLIANT+THERAPEUTICS%2C++++++For%3A+Jun+11++Filed+by%3A+Huh+Hoyoung/26641885.html si-local-file:///var/storage/secattach/20260612/26641885.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++PLIANT+THERAPEUTICS%2C++++++For%3A+Jun+11++Filed+by%3A+Huh+Hoyoung/26641885.html Fri, 12 Jun 2026 17:01:00 -0400 O.38968346 PLRX http://www.streetinsider.com/SEC+Filings/Form++4++++++++++PLIANT+THERAPEUTICS%2C++++++For%3A+Jun+11++Filed+by%3A+Huh+Hoyoung/26641885.html si-local-file:///var/storage/secattach/20260612/26641885.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++PLIANT+THERAPEUTICS%2C++++++For%3A+Jun+11++Filed+by%3A+Huh+Hoyoung/26641885.html Fri, 12 Jun 2026 17:01:00 -0400 O.38968346 PLRX http://www.streetinsider.com/SEC+Filings/Form++4++++++++++PLIANT+THERAPEUTICS%2C++++++For%3A+Jun+11++Filed+by%3A+CROWELL+GAYLE+A/26641886.html si-local-file:///var/storage/secattach/20260612/26641886.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++PLIANT+THERAPEUTICS%2C++++++For%3A+Jun+11++Filed+by%3A+CROWELL+GAYLE+A/26641886.html Fri, 12 Jun 2026 17:01:00 -0400 O.38968346 PLRX http://www.streetinsider.com/SEC+Filings/Form++4++++++++++PLIANT+THERAPEUTICS%2C++++++For%3A+Jun+11++Filed+by%3A+CROWELL+GAYLE+A/26641886.html si-local-file:///var/storage/secattach/20260612/26641886.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++PLIANT+THERAPEUTICS%2C++++++For%3A+Jun+11++Filed+by%3A+CROWELL+GAYLE+A/26641886.html Fri, 12 Jun 2026 17:01:00 -0400 O.38968346 PLRX http://www.streetinsider.com/SEC+Filings/Form++4++++++++++PLIANT+THERAPEUTICS%2C++++++For%3A+Jun+11++Filed+by%3A+MCCOURT+Thomas+A/26641887.html si-local-file:///var/storage/secattach/20260612/26641887.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++PLIANT+THERAPEUTICS%2C++++++For%3A+Jun+11++Filed+by%3A+MCCOURT+Thomas+A/26641887.html Fri, 12 Jun 2026 17:01:00 -0400 O.38968346 PLRX http://www.streetinsider.com/SEC+Filings/Form++4++++++++++PLIANT+THERAPEUTICS%2C++++++For%3A+Jun+11++Filed+by%3A+MCCOURT+Thomas+A/26641887.html si-local-file:///var/storage/secattach/20260612/26641887.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++PLIANT+THERAPEUTICS%2C++++++For%3A+Jun+11++Filed+by%3A+MCCOURT+Thomas+A/26641887.html Fri, 12 Jun 2026 17:01:00 -0400 O.38968346 PLRX http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++PLIANT+THERAPEUTICS%2C++++++For%3A+Jun+11/26636545.html si-local-file:///var/storage/secattach/20260611/26636545.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++PLIANT+THERAPEUTICS%2C++++++For%3A+Jun+11/26636545.html Thu, 11 Jun 2026 16:52:00 -0400 O.38968346 PLRX http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++PLIANT+THERAPEUTICS%2C++++++For%3A+Jun+11/26636545.html si-local-file:///var/storage/secattach/20260611/26636545.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++PLIANT+THERAPEUTICS%2C++++++For%3A+Jun+11/26636545.html Thu, 11 Jun 2026 16:52:00 -0400 O.38968346 PLRX http://www.streetinsider.com/Corporate+News/Pliant+Therapeutics+to+present+cancer+drug+data+at+ASCO+meeting/26537021.html <p>Pliant Therapeutics Inc. (NASDAQ: PLRX) will present data on its experimental cancer drug PLN-101095 at the 2026 American Society of Clinical Oncology Annual Meeting, scheduled for May 29 to June 2 in Chicago.</p><p>The poster presentation will focus on a cohort expansion of a Phase 1 study evaluating PLN-101095, described as a dual αvβ8/αvβ1 integrin inhibitor, in combination with pembrolizumab for patients with advanced solid tumors that have not responded to immune checkpoint inhibitors. Timothy A. Yap from the University of Texas M.D. Anderson Cancer Center will present the findings on May 30.</p><p>PLN-101095 is currently being tested in FORTIFY, a Phase http://www.streetinsider.com/Corporate+News/Pliant+Therapeutics+to+present+cancer+drug+data+at+ASCO+meeting/26537021.html Thu, 21 May 2026 17:36:28 -0400 PLRX http://www.streetinsider.com/Press+Releases/Pliant+Therapeutics+Announces+Upcoming+Presentation+at+the+2026+American+Society+of+Clinical+Oncology+Annual+Meeting/26536983.html <p align="center"><em>Highlights FORTIFY, the Phase 1b indication expansion trial of PLN-101095 </em><br/><em>enrolling patients with ICI-refractory solid tumors</em></p> <p>SOUTH SAN FRANCISCO, Calif., May 21, 2026 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX) today announced a presentation at the upcoming 2026 American Society of Clinical Oncology (ASCO) Annual Meeting taking place in Chicago, Illinois from May 29 to June 2, 2026.</p> <p><strong>Poster Presentation</strong></p> <p><strong>Title:</strong> <a target="_blank" href="https://www.globenewswire.com/Tracker?data=7n4Ka6859iALwU6Mw1jh49LI_APJ74da7mXg_CS3hUOV1mdACR6SbwDHsc4e5rFvLDCFs2gDyErHwUBxV5nhSc5ryvTj1Cxvnig1auGiicMH1agZz8k_uOpv2FLebMdzPBNcuaciYoZp8W690Q_po0UftwoPpT89V0gbtF10FSpoTo_Z5odFEHukfNyB-nd3GPUWpMQQfO1n6e91K0rkHFUi0JV_UeO_JiowAsWNDEb7L5R8rV1qCv-UrnPcnFoh-6c0hmhN8wxLeyBgRBhwtgjnuiRuQWryz0OF8ZYerTQGjrqLkgaSJeVatqyj9mzMRkmxDLr38fWlm4w2ih_0uVISsfjm88Ic1PGuCodrX4hXRnk55hUelk25g8LyUgT9aWNh1JbAaseKnHdtxszxew==" rel="nofollow" target="_blank">Cohort Expansion of a Phase I Study of PLN-101095, a First-in-Class Dual αvβ8 /αvβ1 Integrin Inhibitor, in Combination with Pembrolizumab in Patients with Advanced Solid Tumors Refractory to Immune http://www.streetinsider.com/Press+Releases/Pliant+Therapeutics+Announces+Upcoming+Presentation+at+the+2026+American+Society+of+Clinical+Oncology+Annual+Meeting/26536983.html Thu, 21 May 2026 17:29:00 -0400 A.33615634 A.50216726 O.07116439 O.21612337 O.38968346 PLRX http://www.streetinsider.com/Press+Releases/Pliant+Therapeutics+Announces+Upcoming+Presentation+at+the+2026+American+Society+of+Clinical+Oncology+Annual+Meeting/26536983.html <p align="center"><em>Highlights FORTIFY, the Phase 1b indication expansion trial of PLN-101095 </em><br/><em>enrolling patients with ICI-refractory solid tumors</em></p> <p>SOUTH SAN FRANCISCO, Calif., May 21, 2026 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX) today announced a presentation at the upcoming 2026 American Society of Clinical Oncology (ASCO) Annual Meeting taking place in Chicago, Illinois from May 29 to June 2, 2026.</p> <p><strong>Poster Presentation</strong></p> <p><strong>Title:</strong> <a target="_blank" href="https://www.globenewswire.com/Tracker?data=7n4Ka6859iALwU6Mw1jh49LI_APJ74da7mXg_CS3hUOV1mdACR6SbwDHsc4e5rFvLDCFs2gDyErHwUBxV5nhSc5ryvTj1Cxvnig1auGiicMH1agZz8k_uOpv2FLebMdzPBNcuaciYoZp8W690Q_po0UftwoPpT89V0gbtF10FSpoTo_Z5odFEHukfNyB-nd3GPUWpMQQfO1n6e91K0rkHFUi0JV_UeO_JiowAsWNDEb7L5R8rV1qCv-UrnPcnFoh-6c0hmhN8wxLeyBgRBhwtgjnuiRuQWryz0OF8ZYerTQGjrqLkgaSJeVatqyj9mzMRkmxDLr38fWlm4w2ih_0uVISsfjm88Ic1PGuCodrX4hXRnk55hUelk25g8LyUgT9aWNh1JbAaseKnHdtxszxew==" rel="nofollow" target="_blank">Cohort Expansion of a Phase I Study of PLN-101095, a First-in-Class Dual αvβ8 /αvβ1 Integrin Inhibitor, in Combination with Pembrolizumab in Patients with Advanced Solid Tumors Refractory to Immune http://www.streetinsider.com/Press+Releases/Pliant+Therapeutics+Announces+Upcoming+Presentation+at+the+2026+American+Society+of+Clinical+Oncology+Annual+Meeting/26536983.html Thu, 21 May 2026 17:29:00 -0400 A.33615634 A.50216726 O.07116439 O.21612337 O.38968346 PLRX http://www.streetinsider.com/Press+Releases/Pliant+Therapeutics+Announces+Upcoming+Presentation+at+the+2026+American+Society+of+Clinical+Oncology+Annual+Meeting/26536983.html <p align="center"><em>Highlights FORTIFY, the Phase 1b indication expansion trial of PLN-101095 </em><br/><em>enrolling patients with ICI-refractory solid tumors</em></p> <p>SOUTH SAN FRANCISCO, Calif., May 21, 2026 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX) today announced a presentation at the upcoming 2026 American Society of Clinical Oncology (ASCO) Annual Meeting taking place in Chicago, Illinois from May 29 to June 2, 2026.</p> <p><strong>Poster Presentation</strong></p> <p><strong>Title:</strong> <a target="_blank" href="https://www.globenewswire.com/Tracker?data=7n4Ka6859iALwU6Mw1jh49LI_APJ74da7mXg_CS3hUOV1mdACR6SbwDHsc4e5rFvLDCFs2gDyErHwUBxV5nhSc5ryvTj1Cxvnig1auGiicMH1agZz8k_uOpv2FLebMdzPBNcuaciYoZp8W690Q_po0UftwoPpT89V0gbtF10FSpoTo_Z5odFEHukfNyB-nd3GPUWpMQQfO1n6e91K0rkHFUi0JV_UeO_JiowAsWNDEb7L5R8rV1qCv-UrnPcnFoh-6c0hmhN8wxLeyBgRBhwtgjnuiRuQWryz0OF8ZYerTQGjrqLkgaSJeVatqyj9mzMRkmxDLr38fWlm4w2ih_0uVISsfjm88Ic1PGuCodrX4hXRnk55hUelk25g8LyUgT9aWNh1JbAaseKnHdtxszxew==" rel="nofollow" target="_blank">Cohort Expansion of a Phase I Study of PLN-101095, a First-in-Class Dual αvβ8 /αvβ1 Integrin Inhibitor, in Combination with Pembrolizumab in Patients with Advanced Solid Tumors Refractory to Immune http://www.streetinsider.com/Press+Releases/Pliant+Therapeutics+Announces+Upcoming+Presentation+at+the+2026+American+Society+of+Clinical+Oncology+Annual+Meeting/26536983.html Thu, 21 May 2026 17:29:00 -0400 A.33615634 A.50216726 O.07116439 O.21612337 O.38968346 PLRX http://www.streetinsider.com/Press+Releases/Pliant+Therapeutics+Announces+Upcoming+Presentation+at+the+2026+American+Society+of+Clinical+Oncology+Annual+Meeting/26536983.html <p align="center"><em>Highlights FORTIFY, the Phase 1b indication expansion trial of PLN-101095 </em><br/><em>enrolling patients with ICI-refractory solid tumors</em></p> <p>SOUTH SAN FRANCISCO, Calif., May 21, 2026 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX) today announced a presentation at the upcoming 2026 American Society of Clinical Oncology (ASCO) Annual Meeting taking place in Chicago, Illinois from May 29 to June 2, 2026.</p> <p><strong>Poster Presentation</strong></p> <p><strong>Title:</strong> <a target="_blank" href="https://www.globenewswire.com/Tracker?data=7n4Ka6859iALwU6Mw1jh49LI_APJ74da7mXg_CS3hUOV1mdACR6SbwDHsc4e5rFvLDCFs2gDyErHwUBxV5nhSc5ryvTj1Cxvnig1auGiicMH1agZz8k_uOpv2FLebMdzPBNcuaciYoZp8W690Q_po0UftwoPpT89V0gbtF10FSpoTo_Z5odFEHukfNyB-nd3GPUWpMQQfO1n6e91K0rkHFUi0JV_UeO_JiowAsWNDEb7L5R8rV1qCv-UrnPcnFoh-6c0hmhN8wxLeyBgRBhwtgjnuiRuQWryz0OF8ZYerTQGjrqLkgaSJeVatqyj9mzMRkmxDLr38fWlm4w2ih_0uVISsfjm88Ic1PGuCodrX4hXRnk55hUelk25g8LyUgT9aWNh1JbAaseKnHdtxszxew==" rel="nofollow" target="_blank">Cohort Expansion of a Phase I Study of PLN-101095, a First-in-Class Dual αvβ8 /αvβ1 Integrin Inhibitor, in Combination with Pembrolizumab in Patients with Advanced Solid Tumors Refractory to Immune http://www.streetinsider.com/Press+Releases/Pliant+Therapeutics+Announces+Upcoming+Presentation+at+the+2026+American+Society+of+Clinical+Oncology+Annual+Meeting/26536983.html Thu, 21 May 2026 17:29:00 -0400 A.33615634 A.50216726 O.07116439 O.21612337 O.38968346 PLRX http://www.streetinsider.com/Press+Releases/Pliant+Therapeutics+Announces+Upcoming+Presentation+at+the+2026+American+Society+of+Clinical+Oncology+Annual+Meeting/26536983.html <p align="center"><em>Highlights FORTIFY, the Phase 1b indication expansion trial of PLN-101095 </em><br/><em>enrolling patients with ICI-refractory solid tumors</em></p> <p>SOUTH SAN FRANCISCO, Calif., May 21, 2026 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX) today announced a presentation at the upcoming 2026 American Society of Clinical Oncology (ASCO) Annual Meeting taking place in Chicago, Illinois from May 29 to June 2, 2026.</p> <p><strong>Poster Presentation</strong></p> <p><strong>Title:</strong> <a target="_blank" href="https://www.globenewswire.com/Tracker?data=7n4Ka6859iALwU6Mw1jh49LI_APJ74da7mXg_CS3hUOV1mdACR6SbwDHsc4e5rFvLDCFs2gDyErHwUBxV5nhSc5ryvTj1Cxvnig1auGiicMH1agZz8k_uOpv2FLebMdzPBNcuaciYoZp8W690Q_po0UftwoPpT89V0gbtF10FSpoTo_Z5odFEHukfNyB-nd3GPUWpMQQfO1n6e91K0rkHFUi0JV_UeO_JiowAsWNDEb7L5R8rV1qCv-UrnPcnFoh-6c0hmhN8wxLeyBgRBhwtgjnuiRuQWryz0OF8ZYerTQGjrqLkgaSJeVatqyj9mzMRkmxDLr38fWlm4w2ih_0uVISsfjm88Ic1PGuCodrX4hXRnk55hUelk25g8LyUgT9aWNh1JbAaseKnHdtxszxew==" rel="nofollow" target="_blank">Cohort Expansion of a Phase I Study of PLN-101095, a First-in-Class Dual αvβ8 /αvβ1 Integrin Inhibitor, in Combination with Pembrolizumab in Patients with Advanced Solid Tumors Refractory to Immune http://www.streetinsider.com/Press+Releases/Pliant+Therapeutics+Announces+Upcoming+Presentation+at+the+2026+American+Society+of+Clinical+Oncology+Annual+Meeting/26536983.html Thu, 21 May 2026 17:29:00 -0400 A.33615634 A.50216726 O.07116439 O.21612337 O.38968346 PLRX http://www.streetinsider.com/Press+Releases/Pliant+Therapeutics+Announces+Upcoming+Presentation+at+the+2026+American+Society+of+Clinical+Oncology+Annual+Meeting/26536983.html <p align="center"><em>Highlights FORTIFY, the Phase 1b indication expansion trial of PLN-101095 </em><br/><em>enrolling patients with ICI-refractory solid tumors</em></p> <p>SOUTH SAN FRANCISCO, Calif., May 21, 2026 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX) today announced a presentation at the upcoming 2026 American Society of Clinical Oncology (ASCO) Annual Meeting taking place in Chicago, Illinois from May 29 to June 2, 2026.</p> <p><strong>Poster Presentation</strong></p> <p><strong>Title:</strong> <a target="_blank" href="https://www.globenewswire.com/Tracker?data=7n4Ka6859iALwU6Mw1jh49LI_APJ74da7mXg_CS3hUOV1mdACR6SbwDHsc4e5rFvLDCFs2gDyErHwUBxV5nhSc5ryvTj1Cxvnig1auGiicMH1agZz8k_uOpv2FLebMdzPBNcuaciYoZp8W690Q_po0UftwoPpT89V0gbtF10FSpoTo_Z5odFEHukfNyB-nd3GPUWpMQQfO1n6e91K0rkHFUi0JV_UeO_JiowAsWNDEb7L5R8rV1qCv-UrnPcnFoh-6c0hmhN8wxLeyBgRBhwtgjnuiRuQWryz0OF8ZYerTQGjrqLkgaSJeVatqyj9mzMRkmxDLr38fWlm4w2ih_0uVISsfjm88Ic1PGuCodrX4hXRnk55hUelk25g8LyUgT9aWNh1JbAaseKnHdtxszxew==" rel="nofollow" target="_blank">Cohort Expansion of a Phase I Study of PLN-101095, a First-in-Class Dual αvβ8 /αvβ1 Integrin Inhibitor, in Combination with Pembrolizumab in Patients with Advanced Solid Tumors Refractory to Immune http://www.streetinsider.com/Press+Releases/Pliant+Therapeutics+Announces+Upcoming+Presentation+at+the+2026+American+Society+of+Clinical+Oncology+Annual+Meeting/26536983.html Thu, 21 May 2026 17:29:00 -0400 A.33615634 A.50216726 O.07116439 O.21612337 O.38968346 PLRX http://www.streetinsider.com/Globe+Newswire/Pliant+Therapeutics+Announces+Upcoming+Presentation+at+the+2026+American+Society+of+Clinical+Oncology+Annual+Meeting/26536983.html <p align="center"><em>Highlights FORTIFY, the Phase 1b indication expansion trial of PLN-101095 </em><br/><em>enrolling patients with ICI-refractory solid tumors</em></p> <p>SOUTH SAN FRANCISCO, Calif., May 21, 2026 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX) today announced a presentation at the upcoming 2026 American Society of Clinical Oncology (ASCO) Annual Meeting taking place in Chicago, Illinois from May 29 to June 2, 2026.</p> <p><strong>Poster Presentation</strong></p> <p><strong>Title:</strong> <a target="_blank" href="https://www.globenewswire.com/Tracker?data=7n4Ka6859iALwU6Mw1jh49LI_APJ74da7mXg_CS3hUOV1mdACR6SbwDHsc4e5rFvLDCFs2gDyErHwUBxV5nhSc5ryvTj1Cxvnig1auGiicMH1agZz8k_uOpv2FLebMdzPBNcuaciYoZp8W690Q_po0UftwoPpT89V0gbtF10FSpoTo_Z5odFEHukfNyB-nd3GPUWpMQQfO1n6e91K0rkHFUi0JV_UeO_JiowAsWNDEb7L5R8rV1qCv-UrnPcnFoh-6c0hmhN8wxLeyBgRBhwtgjnuiRuQWryz0OF8ZYerTQGjrqLkgaSJeVatqyj9mzMRkmxDLr38fWlm4w2ih_0uVISsfjm88Ic1PGuCodrX4hXRnk55hUelk25g8LyUgT9aWNh1JbAaseKnHdtxszxew==" rel="nofollow" target="_blank">Cohort Expansion of a Phase I Study of PLN-101095, a First-in-Class Dual αvβ8 /αvβ1 Integrin Inhibitor, in Combination with Pembrolizumab in Patients with Advanced Solid Tumors Refractory to Immune http://www.streetinsider.com/Globe+Newswire/Pliant+Therapeutics+Announces+Upcoming+Presentation+at+the+2026+American+Society+of+Clinical+Oncology+Annual+Meeting/26536983.html Thu, 21 May 2026 17:29:00 -0400 A.33615634 A.50216726 O.07116439 O.21612337 O.38968346 PLRX http://www.streetinsider.com/Globe+Newswire/Pliant+Therapeutics+Announces+Upcoming+Presentation+at+the+2026+American+Society+of+Clinical+Oncology+Annual+Meeting/26536983.html <p align="center"><em>Highlights FORTIFY, the Phase 1b indication expansion trial of PLN-101095 </em><br/><em>enrolling patients with ICI-refractory solid tumors</em></p> <p>SOUTH SAN FRANCISCO, Calif., May 21, 2026 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX) today announced a presentation at the upcoming 2026 American Society of Clinical Oncology (ASCO) Annual Meeting taking place in Chicago, Illinois from May 29 to June 2, 2026.</p> <p><strong>Poster Presentation</strong></p> <p><strong>Title:</strong> <a target="_blank" href="https://www.globenewswire.com/Tracker?data=7n4Ka6859iALwU6Mw1jh49LI_APJ74da7mXg_CS3hUOV1mdACR6SbwDHsc4e5rFvLDCFs2gDyErHwUBxV5nhSc5ryvTj1Cxvnig1auGiicMH1agZz8k_uOpv2FLebMdzPBNcuaciYoZp8W690Q_po0UftwoPpT89V0gbtF10FSpoTo_Z5odFEHukfNyB-nd3GPUWpMQQfO1n6e91K0rkHFUi0JV_UeO_JiowAsWNDEb7L5R8rV1qCv-UrnPcnFoh-6c0hmhN8wxLeyBgRBhwtgjnuiRuQWryz0OF8ZYerTQGjrqLkgaSJeVatqyj9mzMRkmxDLr38fWlm4w2ih_0uVISsfjm88Ic1PGuCodrX4hXRnk55hUelk25g8LyUgT9aWNh1JbAaseKnHdtxszxew==" rel="nofollow" target="_blank">Cohort Expansion of a Phase I Study of PLN-101095, a First-in-Class Dual αvβ8 /αvβ1 Integrin Inhibitor, in Combination with Pembrolizumab in Patients with Advanced Solid Tumors Refractory to Immune http://www.streetinsider.com/Globe+Newswire/Pliant+Therapeutics+Announces+Upcoming+Presentation+at+the+2026+American+Society+of+Clinical+Oncology+Annual+Meeting/26536983.html Thu, 21 May 2026 17:29:00 -0400 A.33615634 A.50216726 O.07116439 O.21612337 O.38968346 PLRX http://www.streetinsider.com/Globe+Newswire/Pliant+Therapeutics+Announces+Upcoming+Presentation+at+the+2026+American+Society+of+Clinical+Oncology+Annual+Meeting/26536983.html <p align="center"><em>Highlights FORTIFY, the Phase 1b indication expansion trial of PLN-101095 </em><br/><em>enrolling patients with ICI-refractory solid tumors</em></p> <p>SOUTH SAN FRANCISCO, Calif., May 21, 2026 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX) today announced a presentation at the upcoming 2026 American Society of Clinical Oncology (ASCO) Annual Meeting taking place in Chicago, Illinois from May 29 to June 2, 2026.</p> <p><strong>Poster Presentation</strong></p> <p><strong>Title:</strong> <a target="_blank" href="https://www.globenewswire.com/Tracker?data=7n4Ka6859iALwU6Mw1jh49LI_APJ74da7mXg_CS3hUOV1mdACR6SbwDHsc4e5rFvLDCFs2gDyErHwUBxV5nhSc5ryvTj1Cxvnig1auGiicMH1agZz8k_uOpv2FLebMdzPBNcuaciYoZp8W690Q_po0UftwoPpT89V0gbtF10FSpoTo_Z5odFEHukfNyB-nd3GPUWpMQQfO1n6e91K0rkHFUi0JV_UeO_JiowAsWNDEb7L5R8rV1qCv-UrnPcnFoh-6c0hmhN8wxLeyBgRBhwtgjnuiRuQWryz0OF8ZYerTQGjrqLkgaSJeVatqyj9mzMRkmxDLr38fWlm4w2ih_0uVISsfjm88Ic1PGuCodrX4hXRnk55hUelk25g8LyUgT9aWNh1JbAaseKnHdtxszxew==" rel="nofollow" target="_blank">Cohort Expansion of a Phase I Study of PLN-101095, a First-in-Class Dual αvβ8 /αvβ1 Integrin Inhibitor, in Combination with Pembrolizumab in Patients with Advanced Solid Tumors Refractory to Immune http://www.streetinsider.com/Globe+Newswire/Pliant+Therapeutics+Announces+Upcoming+Presentation+at+the+2026+American+Society+of+Clinical+Oncology+Annual+Meeting/26536983.html Thu, 21 May 2026 17:29:00 -0400 A.33615634 A.50216726 O.07116439 O.21612337 O.38968346 PLRX http://www.streetinsider.com/Globe+Newswire/Pliant+Therapeutics+Announces+Upcoming+Presentation+at+the+2026+American+Society+of+Clinical+Oncology+Annual+Meeting/26536983.html <p align="center"><em>Highlights FORTIFY, the Phase 1b indication expansion trial of PLN-101095 </em><br/><em>enrolling patients with ICI-refractory solid tumors</em></p> <p>SOUTH SAN FRANCISCO, Calif., May 21, 2026 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX) today announced a presentation at the upcoming 2026 American Society of Clinical Oncology (ASCO) Annual Meeting taking place in Chicago, Illinois from May 29 to June 2, 2026.</p> <p><strong>Poster Presentation</strong></p> <p><strong>Title:</strong> <a target="_blank" href="https://www.globenewswire.com/Tracker?data=7n4Ka6859iALwU6Mw1jh49LI_APJ74da7mXg_CS3hUOV1mdACR6SbwDHsc4e5rFvLDCFs2gDyErHwUBxV5nhSc5ryvTj1Cxvnig1auGiicMH1agZz8k_uOpv2FLebMdzPBNcuaciYoZp8W690Q_po0UftwoPpT89V0gbtF10FSpoTo_Z5odFEHukfNyB-nd3GPUWpMQQfO1n6e91K0rkHFUi0JV_UeO_JiowAsWNDEb7L5R8rV1qCv-UrnPcnFoh-6c0hmhN8wxLeyBgRBhwtgjnuiRuQWryz0OF8ZYerTQGjrqLkgaSJeVatqyj9mzMRkmxDLr38fWlm4w2ih_0uVISsfjm88Ic1PGuCodrX4hXRnk55hUelk25g8LyUgT9aWNh1JbAaseKnHdtxszxew==" rel="nofollow" target="_blank">Cohort Expansion of a Phase I Study of PLN-101095, a First-in-Class Dual αvβ8 /αvβ1 Integrin Inhibitor, in Combination with Pembrolizumab in Patients with Advanced Solid Tumors Refractory to Immune http://www.streetinsider.com/Globe+Newswire/Pliant+Therapeutics+Announces+Upcoming+Presentation+at+the+2026+American+Society+of+Clinical+Oncology+Annual+Meeting/26536983.html Thu, 21 May 2026 17:29:00 -0400 A.33615634 A.50216726 O.07116439 O.21612337 O.38968346 PLRX